Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership

Brainomix – the AI-powered MedTech solutions company – and Bridge Biotherapeutics, a clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, have announced a new partnership. The collaboration will deliver quantitative imaging biomarker analysis within the phase 2 study of novel autotaxin inhibitor BBT-877, which has been designed to evaluate the safety, tolerability and efficacy in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology – automated artificial intelligence software – which has been trained to process high resolution chest CT data in patients with interstitial lung diseases, including IPF and other conditions that cause progressive pulmonary fibrosis. Clinical trials in IPF commonly rely on serial physiological measurement of forced vital capacity as trial endpoints, which can be highly variable from day-to-day for any individual patient. Meanwhile, automated AI-powered quantitative imaging has the potential to significantly improve trial design, improve the chances of identifying a positive treatment response and accelerate the translation of new treatments into clinical practice.